Novamab

Novamab is a biotech company in Shanghai, China, founded in 2017. It has raised $84.8M across 3 rounds, most recently a $31.6M Series B in April 2024.

Headquarters
Shanghai
Employees
51–200
Founded
2017
Business Model
B2B
Total Funding
$84.8M
Last Round
$31.6M Series BApr 2024
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 3 investors for this company. The full record is or through the API.

About

NovaMab (Shanghai Novamab Biopharmaceuticals Co., Ltd.) is a clinical-stage biotech company founded in 2017 and headquartered in the Shanghai International Medical Park, Pudong New Area, Shanghai, China. The company is dedicated to creating life-changing therapies through innovative VHH (single domain antibody) technology, with a highly differentiated pipeline targeting high-potential markets including asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). NovaMab's most advanced program, an inhaled IL-4R VHH antibody (LQ036), has progressed to Phase IIb clinical trials, while its inhaled TSLP VHH (LQ043H) is entering Phase IB studies. The company operates a 500L GMP workshop for VHH antibody production using Pichia pastoris, holds over 100 patents, and has been recognized among China's top 50 innovative biopharmaceutical enterprises.

Summary

It lists 51–200 employees. It has raised $84.8M in total across 3 rounds, most recently a $31.6M Series B round in Apr 2024. Investors include Qiming VP, Huangpu Biomedical Fund and Jiuyu Investment.

Funding History

Data from Indexed.vcUpdated
Series BSeries BApr 2024
$31.6M

Sign up to see all 3 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Novamab on Indexed.vc
<a href="https://indexed.vc/companies/novamab"><img src="https://indexed.vc/api/badge/company/novamab" alt="Novamab on Indexed.vc" width="260" height="76" /></a>